About Us

Founded in 1981, Britannia Pharmaceuticals Limited is a UK based niche pharmaceutical company specialising in products for diseases with orphan indications (small patient populations) which are normally not developed by larger pharmaceutical companies.  Subsequent to recent acquisition Britannia is now part of the STADA group of companies.

Our primary expertise is in the development and marketing of products in the area of Parkinson's disease. Active for nearly 30 years with UK neurologists and geriatricians, we identified the benefit of and need for apomorphine as a treatment for Parkinson's disease sufferers, leading to the development of our APO-go® products. 

Additionally we have developed non-opiate based therapeutics to assist in opiate detoxification and withdrawal, and have made advances in the areas of wound healing and respiratory disorders

Britannia’s management team is comprised of experienced professionals with extensive knowledge of the pharmaceutical industry and drug development.  We maintain close ties with key opinion leaders throughout the research and development process for each of our marketed products and those in development.